[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354930-105":3,"doc-detail-354930-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","non-canonical-senescence-phenotype-in-resistance-to-cdk46-inhibitors-in-er-positive-breast-cancer","Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast Cancer","","Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have reshaped treatment for estrogen receptor-positive (ER+) breast cancer, yet therapeutic resistance remains a major obstacle. This study generates palbociclib- and abemaciclib-resistant ER+ breast cancer sublines via prolonged drug exposure and characterizes the resulting resistant phenotypes. Resistant cells show senescence-like changes with mitochondrial and metabolic defects, alongside a non-canonical SASP marked by elevated GDF-15 and serpin E1/PAI-1 and absence of classical inflammatory interleukins. Notably, IL-8 increases without EMT association, epithelial features persist, stem-like ALDH1+ populations are absent, and RANTES is strongly upregulated in palbociclib-resistant cells.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/non-canonical-senescence-phenotype-in-resistance-to-cdk46-inhibitors-in-er-positive-breast-cancer/354930/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/non-canonical-senescence-phenotype-in-resistance-to-cdk46-inhibitors-in-er-positive-breast-cancer/354930.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-09","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were CDK4/6 inhibitor-resistant ER+ breast cancer sublines generated?","Question",{"text":63,"@type":64},"Resistant ER+ breast cancer sublines were developed by prolonged drug exposure over six months using palbociclib (2PR, 9PR, TPR) and abemaciclib (2AR, 9AR, TAR).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What defines the non-canonical senescence phenotype in resistant cells?",{"text":68,"@type":64},"Resistant cells exhibit cellular senescence with reduced mitochondrial membrane potential and impaired glycolysis, together with a non-canonical SASP characterized by elevated GDF-15 and serpin E1/PAI-1 and absence of classical pro-inflammatory interleukins such as IL-1α and IL-6.",{"name":70,"@type":61,"acceptedAnswer":71},"Does the resistance-associated senescence involve EMT or stem-like populations?",{"text":72,"@type":64},"No association with epithelial–mesenchymal transition (EMT) was observed, epithelial morphology was preserved without EMT marker upregulation, and aldehyde dehydrogenase 1-positive (ALDH1+) stem-like populations were absent.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354930,1790782290,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d",8,"Article  \nNon-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast Cancer  \nAynura Mammadova 1, Yuan Gu 1, Ling Ruan 1, Sunil S. Badve 1,2,† and Yesim Gökmen-Polar 1,2, *,†  \nAcademic Editor: Norbert Nass  \nReceived: 5 November 2025  \nRevised: 28 December 2025  \nAccepted: 3 January 2026  \nPublished: 6 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA; [sbadve@emory.edu](sbadve@emory.edu) (S.S.B.)  \n2 Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA  \n* [Correspondence: ypolar@emory.edu](Correspondence: ypolar@emory.edu)[ ](Correspondence: ypolar@emory.edu)† These authors contributed equally to this work.  \nAbstract  \nCyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have transformed the treatment landscape for estrogen receptor-positive (ER+) breast cancer, yet resistance remains a major clinical challenge. Although CDK4/6i induce G 1 arrest and therapy-induced senescence (TIS), the exact nature of this senescent state and its contribution to resistance are not well understood. To explore this, we developed palbociclib- (2PR, 9PR, TPR) and abemaciclib-(2AR, 9AR, TAR) resistant ER+ breast cancer sublines through prolonged drug exposure over six months. Resistant cells demonstrated distinct phenotypic alterations, including cellular senescence, reduced mitochondrial membrane potential, and impaired glycolytic activity. Cytokine profiling and enzyme-linked immunosorbent assay (ELISA) validation revealed a non-canonical senescence-associated secretory phenotype (SASP) characterized by elevated growth/differentiation factor 15 (GDF-15) and serpin E1 (plasminogen activator inhibitor-1, PAI-1) and absence of classical pro-inflammatory interleukins, including IL-1α and IL-6 . IL-8 levels were significantly elevated, but no association with epithelial–mesenchymal transition (EMT) was observed. Resistant cells preserved their epithelial morphology, showed no upregulation of EMT markers, and lacked aldehyde dehydrogenase 1-positive (ALDH1+) stem-like populations. Additionally, Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES) was strongly upregulated in palbociclib-resistant cells. Together, these findings identify a distinct, non-canonical senescence phenotype associated with CDK4/6i resistance and may provide a foundation for identifying new vulnerabilities in resistant ER+ breast cancers through targeting SASP-related signaling.  \nKeywords: breast cancer; CDK4/6 inhibitors; resistance to cancer therapies; therapy-induced senescence  \n1. Introduction  \nCyclin-dependent kinase 4/6 inhibitors (CDK4/6i), palbociclib, ribociclib, and abemaciclib, have introduced a new era in the treatment of estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer. Landmark clinical trials, such as PALOMA, MONALEESA, and MONARCH, have demonstrated significant improvements in progression-free survival when these agents are combined with endocrine therapy in both first-and second-line metastatic settings [1,2] . The MONARCH-2 trial also demonstrated an overall survival benefit, further reinforcing the role of CDK4/6i as standard of  \ncare in advanced disease. These findings have established CDK4/6i as a standard of care in advanced ER+ breast cancer [3] .  \nMechanistically, CDK4/6i exert their therapeutic effect by blocking CDK4/6 and cyclin D complexes and Rb phosphorylation, leading to a G 1 cell cycle arrest [4] . CDK4/6 inhibition also induces a phenotype resembling cellular senescence in vitro, given the key role of the retinoblastoma (RB) protein in the regulation of senescence. This therapy-induced senescence (TIS) represents a cellular state of persistent cell cycle exit with associa","cbCaisYsuWlK38QA","https://ap.wps.com/l/cbCaisYsuWlK38QA","pdf",2058888,18,"English","# Introduction\n## CDK4/6 inhibitors and ER+ breast cancer treatment context\n## Mechanistic basis of CDK4/6 inhibitor-induced senescence\n## Senescence dependency on p53, mTOR signaling, and SASP","[{\"question\":\"How were CDK4/6 inhibitor-resistant ER+ breast cancer sublines generated?\",\"answer\":\"Resistant ER+ breast cancer sublines were developed by prolonged drug exposure over six months using palbociclib (2PR, 9PR, TPR) and abemaciclib (2AR, 9AR, TAR).\"},{\"question\":\"What defines the non-canonical senescence phenotype in resistant cells?\",\"answer\":\"Resistant cells exhibit cellular senescence with reduced mitochondrial membrane potential and impaired glycolysis, together with a non-canonical SASP characterized by elevated GDF-15 and serpin E1/PAI-1 and absence of classical pro-inflammatory interleukins such as IL-1α and IL-6.\"},{\"question\":\"Does the resistance-associated senescence involve EMT or stem-like populations?\",\"answer\":\"No association with epithelial–mesenchymal transition (EMT) was observed, epithelial morphology was preserved without EMT marker upregulation, and aldehyde dehydrogenase 1-positive (ALDH1+) stem-like populations were absent.\"}]","Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast Cancer | PDF",1790114911,45,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c47de5e341ef18e51c011762ffe0da1.webp",983,1390,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5d5889bd68a2b7d554cb1190a1dff80.webp",982,1388,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/070bfeab33a04fc57f93eee6fd317702.webp",981,1387,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8991fb8a7b44935856642a53db758fac.webp",980,1385,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,145,148,153,156,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":143,"slug":144},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":146,"slug":147},30,"research-report",{"id":149,"doc_module":4,"doc_module_name":25,"category_name":150,"show_sort_weight":151,"slug":152},9,"Religion & Spirituality",20,"religion-spirituality",{"id":151,"doc_module":4,"doc_module_name":25,"category_name":154,"show_sort_weight":151,"slug":155},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":55,"slug":158},"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]